Bone Abstracts

Background: Sarcopenic obesity is usually defined by the combination of sarcopenia and obesity but there is not a standard definition yet. The recommended method for the quantification of muscle mass is dual energy X-ray absorptiometry (DXA), based on assessment of total fat mass and appendicular lean mass. Low Body Mass Index (BMI) used to be considered as a risk factor for fragility fracture. However, recent evidences have demonstrated a correlation between BMI and vertebral...

Molecules secreted by the osteoclast or ‘clastokynes’ are essential to stimulate bone formation by osteoblasts. Treatments with bisphosphates and Denosumab target osteoclast survival and differentiation. This suppresses bone turnover and is suspected to increase the risk of atypical fractures in the long term. A solution to overcome this is to develop strategies that target selectively the activity of osteoclasts without affecting their survival or differentiation. S...

According various guidelines the basic recommendation in prevention and treatment of postmenopausal osteoporosis (PMO) is adequate intake of calcium (1000– 1300 mg/day) and vitamin D (800–1000 IU/day).Aim: To determine the intake dose of calcium and also the vitamin D saturation in women treated for PMO.Patients and methods: 465 women with PMO, divided into two groups: patients with newly diagnosed osteoporosis (n</em...

Introduction: Denosumab monoclonal antibody approved for Osteoporosis’s treatment in Europe union and U.S.A. Dose of 60 mg every 6 months reduces the risk of vertebral, non vertebral and hip fractures. What is more increases BMDMaterial and methods: Descriptive observational study with densitometric characterisques and risk factors of 64 patients in Osteoporosis unit of HGUG Marañón from November 2011 to December 2013. Analyzing occurrence...

Bone strength is influenced by cortical thickness, area, mass and porosity, all of which contribute to nonvertebral fracture risk. Cortical porosity is one parameter of structural decay associated with bone fragility. This is caused by unbalanced and accelerated remodelling of Haversian units which enlarge, coalesce and fragment the cortex. Antiresorptive therapies will limit progression of cortical porosity; reducing existing porosity would be a goal for those already at incr...

Objectives: We recently identified a heterozygous missense mutation c.652T→G (p. C218G) in WNT1 as the cause of severe primary osteoporosis (Laine et al. New Engl J Med 2013). The mutated WNT1 reduces activation of the canonical WNT1/β-catenin-signaling, resulting in decreased osteoblastic function. The mutation was originally identified in a large Finnish family presenting with dominantly inherited, early-onset osteoporosis, with affected...

Osteogenesis imperfecta (OI) is a heterogeneous group of inherited disorders of bone formation, resulting in low bone mass and an increased propensity to fracture. Over 90% of patients with OI have a mutation in COL1A1/COL1A2, which shows an autosomal dominant pattern of inheritance. Several other genes are associated with the autosomal recessive forms of OI. In-depth phenotyping and in particular, studies involving manifestations in the skin connective tissu...

Although the baby growing in its mother’s womb needs calcium for skeletal development osteoporosis and fractures very rarely occur during pregnancy. Pregnancy- and lactation-associated osteoporosis with the occurrence of fragility fractures mainly of the vertebral bodies was first described as a syndrome Nordin et al. in 1955. It is most commonly observed in the third trimester or early post-partum in women presenting with severe and prolonged back pain and somet...

Calcium supplements are associated with increased cardiovascular risk, but the mechanism by which this occurs is presently uncertain. In a secondary analysis of a trial examining the acute effects of calcium supplements, we found that blood pressure declined over 8 h in the control group, consistent with its diurnal rhythm, and that this decline was smaller in the calcium group [1]. To investigate these effects further, we carried out a randomised controlled cross-over trial o...

CCN2/CTGF is known as a multi-functional growth factor for various mesenchymal cells including chondrocytes, osteoblasts, vascular endothelial cells and its function is suggested to be produced by its binding to other growth factors or membrane proteins. Therefore, finding out these binding partners are critically important in understanding the molecular function of the CCN2. As a result of screening, DCL-1/CD302 was found as a new candidate of CCN2-binding molecule. DCL-1/CD3...